Diagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.
A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves injecting a radioisotope, typically technetium-99m, intravenously to image pulmonary circulation. Ventilation scanning requires the patient to inhale a radioactive gas to visualize air distribution in the lungs. While V/Q scans provide high accuracy, ventilation scanning can be challenging for critically ill or intubated patients.
Certain blood tests, in addition to imaging, can aid in diagnosing PE. The D-dimer test measures cross-linked fibrin fragments and can indicate abnormal clotting activity. Additional diagnostic tools include Chest X-rays, which may reveal nonspecific signs like atelectasis and pleural effusion, and electrocardiograms (ECGs), which can show changes in the ST segment and T wave. Arterial blood gas (ABG) analysis can show low PaO2 levels due to inadequate oxygenation from blocked pulmonary vessels.
Immediate treatment of suspected PE is crucial to reduce mortality and should focus on the patient's cardiorespiratory status. Oxygen therapy should be administered using a mask or cannula, with the fraction of inspired oxygen adjusted based on ABG results to address hypoxemia.
Pulmonary embolism (PE) management is tailored to the patient's status. For stable PE patients, anticoagulant therapy is the cornerstone of treatment.
Anticoagulants such as low-molecular-weight heparin (LMWH), unfractionated heparin, or fondaparinux are recommended to prevent further clot formation. Long-term management involves transitioning to oral anticoagulants like warfarin or direct oral anticoagulants such as rivaroxaban or apixaban, typically continued for at least three months. Regular monitoring of INR levels is necessary for those on warfarin to ensure therapeutic ranges. Dosages are adjusted based on body weight, renal function, and bleeding risk.
In contrast, unstable PE patients, particularly those with hypotension or shock, require more aggressive treatment. Thrombolytic therapy uses tissue plasminogen activators (tPA) like alteplase to rapidly dissolve clots. Supportive measures are critical and include administering supplemental oxygen to manage hypoxemia, providing opioids for pleuritic chest pain, and cautiously using intravenous fluids to maintain blood pressure without overloading the right ventricle. In shock cases, vasopressors such as norepinephrine may be needed to support blood pressure.
For patients with massive PE who cannot undergo thrombolytic therapy, pulmonary embolectomy may be considered. This procedure involves removing emboli, either through a vascular catheter or surgically, to reduce right ventricular afterload. Other moderately invasive procedures for PE include percutaneous interventional techniques, ultrasound-guided catheter thrombolysis, and aspiration thrombectomy.
Lastly, an inferior vena cava (IVC) filter may be considered for patients experiencing recurrent PE despite effective anticoagulation. IVC filters are not recommended as initial treatment and should be avoided in patients already receiving anticoagulants. The filter permits normal blood flow while capturing large emboli from the pelvis or lower extremities, preventing them from reaching the lungs.
Diagnosing pulmonary embolism or PE involves imaging studies, such as CT angiography to visualize the pulmonary vasculature and a ventilation-perfusion scan to visualize pulmonary circulation and lung air distribution.
Additional tests that aid in diagnosing PE are the D-dimer test, which measures cross-linked fibrin fragments, indicating abnormal clotting activity, and ABG analysis, which may show low PaO2 levels. Chest X-rays may reveal nonspecific signs like atelectasis, while ECGs may show changes such as sinus tachycardia.
Next, for stable pulmonary embolism patients without cardiopulmonary instability, anticoagulant therapy should be started immediately with low-molecular-weight heparin or warfarin
For unstable PE patients, particularly those with hypotension or shock, prescribe thrombolytic therapy with a tissue plasminogen activator.
Additionally, Oxygen therapy for hypoxemia, opioids for pleural pain, IV fluids, and vasopressors for circulation support are recommended..
For unstable patients with massive PE and contraindications to thrombolytics, options include pulmonary embolectomy, ultrasound-guided catheter thrombolysis, or aspiration thrombectomy.
繁體中文
